1-14 of 14
George R. Stark
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH1 Expression and Targeting Tumor-Initiating Cells

Free
Sarmishtha De, Daniel J. Lindner, Claire J. Coleman, Gary Wildey, Afshin Dowlati, George R. Stark
Journal: Cancer Research
Series: Author Choice
Cancer Res (2018) 78 (9): 2396–2406.
https://doi.org/10.1158/0008-5472.CAN-17-1920
Published: 30 April 2018
View articletitled, The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH1 Expression and Targeting Tumor-Initiating Cells
Open the PDF for The FACT inhibitor CBL0137 Synergizes with Cisplatin in Small-Cell Lung Cancer by Increasing NOTCH1 Expression and Targeting Tumor-Initiating Cells in another window
Includes: Supplementary data
Journal Articles

Abstract 2884: Interferon Beta (IFN-B) re-activates canonical type I IFN signaling to differentiate breast cancer stem cells (CSCs) and suppress mesenchymal/CSC driven tumor recurrence

Free
Mary R. Doherty, Damian J. Junk, HyeonJoo Cheon, George R. Stark, Mark W. Jackson
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 2884.
https://doi.org/10.1158/1538-7445.AM2017-2884
Published: 01 July 2017
View articletitled, Abstract 2884: Interferon Beta (IFN-B) re-activates canonical type I IFN signaling to differentiate breast cancer stem cells (CSCs) and suppress mesenchymal/CSC driven tumor recurrence
Journal Articles

Abstract 3036: Targeting FACT complex with CBL0137 to overcome acquired resistance to EGFR-TKI in lung adenocarcinoma

Free
Neelesh Sharma, Josephine Dermawan, Andrei Purmal, Daniel Lindner, Gary Wildey, Afshin Dowlati, Andrei Gudkov, Katerina Gurova, George R. Stark
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): 3036.
https://doi.org/10.1158/1538-7445.AM2016-3036
Published: 15 July 2016
View articletitled, Abstract 3036: Targeting FACT complex with CBL0137 to overcome acquired resistance to EGFR-TKI in lung adenocarcinoma
Journal Articles

Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models

Free
Josephine Kam Tai Dermawan, Masahiro Hitomi, Daniel J. Silver, Qiulian Wu, Poorva Sandlesh, Andrew E. Sloan, Andrei A. Purmal, Katerina V. Gurova, Jeremy N. Rich, Justin D. Lathia, George R. Stark, Monica Venere
Journal: Cancer Research
Cancer Res (2016) 76 (8): 2432–2442.
https://doi.org/10.1158/0008-5472.CAN-15-2162
Published: 14 April 2016
View articletitled, Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models
Open the PDF for Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models in another window
Includes: Supplementary data
Journal Articles

NF-κB: Regulation by Methylation

Free
Tao Lu, George R. Stark
Journal: Cancer Research
Cancer Res (2015) 75 (18): 3692–3695.
https://doi.org/10.1158/0008-5472.CAN-15-1022
Published: 14 September 2015
View articletitled, NF-κB: Regulation by Methylation
Open the PDF for NF-κB: Regulation by Methylation in another window
Includes: Supplementary data
Journal Articles

Abstract 485: Chronic exposure to a low dose of interferon-β increases levels of DNA damage resistance signature genes through unphosphorylated ISGF3

Free
HyeonJoo Cheon, Elise G. Holvey-Bates, George R. Stark
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 485.
https://doi.org/10.1158/1538-7445.AM2014-485
Published: 01 October 2014
View articletitled, Abstract 485: Chronic exposure to a low dose of interferon-β increases levels of DNA damage resistance signature genes through unphosphorylated ISGF3
Journal Articles

Overexpression of Kinesins Mediates Docetaxel Resistance in Breast Cancer Cells

Free
Sarmishtha De, Rocky Cipriano, Mark W. Jackson, George R. Stark
Journal: Cancer Research
Cancer Res (2009) 69 (20): 8035–8042.
https://doi.org/10.1158/0008-5472.CAN-09-1224
Published: 14 October 2009
View articletitled, Overexpression of Kinesins Mediates Docetaxel Resistance in Breast Cancer Cells
Open the PDF for Overexpression of Kinesins Mediates Docetaxel Resistance in Breast Cancer Cells in another window
Journal Articles

p53-Mediated Growth Suppression in Response to Nutlin-3 in Cyclin D1–Transformed Cells Occurs Independently of p21

Free
Charlene E. Kan, John T. Patton, George R. Stark, Mark W. Jackson
Journal: Cancer Research
Cancer Res (2007) 67 (20): 9862–9868.
https://doi.org/10.1158/0008-5472.CAN-07-0259
Published: 17 October 2007
View articletitled, p53-Mediated Growth Suppression in Response to Nutlin-3 in Cyclin D1–Transformed Cells Occurs Independently of p21
Open the PDF for p53-Mediated Growth Suppression in Response to Nutlin-3 in Cyclin D1–Transformed Cells Occurs Independently of p21 in another window
Includes: Supplementary data
Journal Articles

MIC-1 mediates p53-dependent protective arrest of cells in S-phase in response to starvation for DNA precursors

Free
Kedar Hastak, Mukesh Agarwal, Mark W. Jackson, Samuel N. Breit, George R. Stark, Munna L. Agarwal
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 754.
Published: 15 April 2006
View articletitled, MIC-1 mediates p53-dependent protective arrest of cells in S-phase in response to starvation for DNA precursors
Journal Articles

Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3

Free
John T. Patton, Lindsey D. Mayo, Aatur D. Singhi, Andrei V. Gudkov, George R. Stark, Mark W. Jackson
Journal: Cancer Research
Cancer Res (2006) 66 (6): 3169–3176.
https://doi.org/10.1158/0008-5472.CAN-05-3832
Published: 15 March 2006
View articletitled, Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3
Open the PDF for Levels of HdmX Expression Dictate the Sensitivity of Normal and Transformed Cells to Nutlin-3 in another window
Journal Articles

Novel Roles of Unphosphorylated STAT3 in Oncogenesis and Transcriptional Regulation

Free
Jinbo Yang, Moitreyee Chatterjee-Kishore, Susan M. Staugaitis, Hannah Nguyen, Karni Schlessinger, David E. Levy, George R. Stark
Journal: Cancer Research
Cancer Res (2005) 65 (3): 939–947.
https://doi.org/10.1158/0008-5472.939.65.3
Published: 10 February 2005
View articletitled, Novel Roles of Unphosphorylated STAT3 in Oncogenesis and Transcriptional Regulation
Open the PDF for Novel Roles of Unphosphorylated STAT3 in Oncogenesis and Transcriptional Regulation in another window
Journal Articles

G2 Arrest in Response to Topoisomerase II Inhibitors: The Role of p53

Free
Brad Clifford, Milos Beljin, George R. Stark, William R. Taylor
Journal: Cancer Research
Cancer Res (2003) 63 (14): 4074–4081.
Published: 21 July 2003
View articletitled, G2 Arrest in Response to Topoisomerase II Inhibitors: The Role of p53
Open the PDF for G2 Arrest in Response to Topoisomerase II Inhibitors: The Role of p53 in another window
Journal Articles

Effects of N-(Phosphonacetyl)-l-aspartate on Murine Tumors and Normal Tissues in Vivo and in Vitro and the Relationship of Sensitivity to Rate of Proliferation and Level of Aspartate Transcarbamylase1

Free
Randall K. Johnson, Elizabeth A. Swyryd, George R. Stark
Journal: Cancer Research
Cancer Res (1978) 38 (2): 371–378.
Published: 01 February 1978
View articletitled, Effects of N-(Phosphonacetyl)-l-aspartate on Murine Tumors and Normal Tissues in Vivo and in Vitro and the Relationship of Sensitivity to Rate of Proliferation and Level of Aspartate Transcarbamylase1
Open the PDF for Effects of N-(Phosphonacetyl)-l-aspartate on Murine Tumors and Normal Tissues in Vivo and in Vitro and the Relationship of Sensitivity to Rate of Proliferation and Level of Aspartate Transcarbamylase1 in another window
Journal Articles

Antitumor Activity of N-(Phosphonacetyl)-L-aspartic Acid, a Transition-State Inhibitor of Aspartate Transcarbamylase

Free
Randall K. Johnson, Toshio Inouye, Abraham Goldin, George R. Stark
Journal: Cancer Research
Cancer Res (1976) 36 (8): 2720–2725.
Published: 01 August 1976
View articletitled, Antitumor Activity of N-(Phosphonacetyl)-L-aspartic Acid, a Transition-State Inhibitor of Aspartate Transcarbamylase
Open the PDF for Antitumor Activity of N-(Phosphonacetyl)-L-aspartic Acid, a Transition-State Inhibitor of Aspartate Transcarbamylase in another window